Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0114 • ACR Convergence 2024
Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cécile Yelnik¹, shruti chaturvedi², Julien Labreuche³, Xiang-Zuo Pan², H Michael Belmont⁴, Nina Kello⁵, Paul Fortin⁶, David Branch⁷, Yu Zuo⁸, Rohan Willis⁹, Robert Brodsky², Jane Salmon¹⁰, Maria Laura Bertolaccini¹¹, Hannah Cohen¹², Michelle Petri¹³ and Doruk Erkan¹⁰, and on behalf of APS ACTION, ¹lille university, Lille, France, ²John Hopkins University, Baltimore, MD, ³Lille University Hospital, Lille, France, ⁴NYU Langone Health, New York, NY, ⁵Northwell Health, Brooklyn, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁷University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Texas Medical Branch, Galveston, TX, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹King's College London, London, United Kingdom, ¹²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We previously reported that markers of complement activation, specifically elevated C4d levels and positive modified HAM (mHAM) test, are associated with a higher risk…
Abstract Number: 0451 • ACR Convergence 2024
Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome
Juan J. Fierro¹, Mirthe Schoots¹, Silvia Liefers¹, Berber Doornbos-van der Meer², Gilles Diercks¹, Hendrika Bootsma³, Jelmer R. Prins¹, Johanna Westra¹ and Karina de Leeuw⁴, ¹University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, ²University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, Groningen, Groningen, Netherlands
Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with…
Abstract Number: 2535 • ACR Convergence 2024
The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation
Chary Lopez-Pedrera¹, Beatriz Vellón-García², Mª Angeles Aguirre-Zamorano³, Sagrario Corrales⁴, Ismael Sánchez Pareja⁴, Laura Muñoz-Barrera⁴, Tomás Cerdó⁴, Pedro Segui⁵, Christian Merlo⁵, María del carmen ábalos-Aguilera⁵, Nuria Barbarroja⁴, Alejandro Escudero-Contreras⁶, Rafaela Ortega-Castro⁷, José Manuel Villalba⁸ and Carlos Perez-Sanchez⁴, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ²Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3) / Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁶Reina Sofia University Hospital, Córdoba, Spain, ⁷Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁸Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3), Cordoba, Spain
Background/Purpose: This study aims to:1) Characterize the circulating lipidomic and proteomic profiles of APS patient and analyse its association with clinical features.2) Investigate the short-term…
Abstract Number: 0099 • ACR Convergence 2024
Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome
Kaitlyn Sabb¹, Ajay Tambralli¹, Megan Radyk¹, Emily Becker¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Cyrus Sarosh², Jacqueline Madison¹, Yu Zuo¹, Costas Lyssiotis¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play important roles in antiphospholipid syndrome (APS) pathogenesis. To kill microbes and propel…
Abstract Number: 0115 • ACR Convergence 2024
Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry
Elena Gkrouzman¹, Ann E. Clarke², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Jose Pardos-Gea⁶, Nina Kello⁷, Diana Paredes-Ruiz⁸, Mª Angeles Aguirre-Zamorano⁹, H Michael Belmont¹⁰, Paul Fortin¹¹, Guilherme Ramires de Jesús¹², Tatsuya Atsumi¹³, Zhuoli Zhang¹⁴, Maria Efthymiou¹⁵, David Branch¹⁶, Giulia Pazzola¹⁷, Laura Andreoli¹⁸, Ali Duarte-Garcia¹⁹, Esther Rodriguez-Almaraz²⁰, Michelle Petri²¹, Ricard Cervera²², Bahar Artim Esen²³, Guillermo Pons-Estel²⁴, Hui Shi²⁵, Jason Knight²⁶, Rohan Willis²⁷, Pierluigi Meroni²⁸, Maria Laura Bertolaccini²⁹, Hannah Cohen³⁰, Robert Roubey³¹, Danieli Andrade³² and Doruk Erkan³³, and on behalf of APS ACTION, ¹University of Massachusetts, Westborough, MA, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ⁵University of Turin, Torino, Turin, Italy, ⁶Vall d'Hebron University Hospital, Barcelona, Spain, ⁷Northwell Health, Brooklyn, NY, ⁸Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ¹⁰NYU School of Medicine, New York, NY, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁴Peking University First Hospital, Beijing, China, ¹⁵University College London, London, United Kingdom, ¹⁶University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁷Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ¹⁸University of Brescia, Brescia, Italy, ¹⁹Mayo Clinic, Rochester, MN, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Timonium, MD, ²²Hospital Clinic de Barcelona, Barcelona, Spain, ²³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁴CREAR, Rosario, Argentina, ²⁵Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), ²⁶University of Michigan, Ann Arbor, MI, ²⁷University of Texas Medical Branch, Galveston, TX, ²⁸IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ²⁹King's College London, London, United Kingdom, ³⁰University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³¹Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ³²University of São Paulo, São Paulo, SP, Brazil, ³³Hospital for Special Surgery, New York, NY
Background/Purpose: The APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune rheumatic diseases…
Abstract Number: 0639 • ACR Convergence 2024
Delayed Diagnosis in Systemic Lupus Erythematosus
Romina Nieto¹, Lucia Hernandez², Nidia Noemí Merás³, Bordón Florencia Juliana⁴, Cintia Otaduy⁵, Lucila Garcia⁶, Rosa Serrano Morales⁷, Nicolás Pérez⁸, Micaela A. Cosatti⁹, Ana Carolina Montandon¹⁰, Gustavo Flores Chapacais¹¹, Laissa C. Alves Alvino¹², Emily Figuereido Neves¹³, Eloisa Bonfa¹⁴, Alexis Bondi Peralta¹⁵, Loreto Massardo¹⁶, Andrés Cadena Bonfanti¹⁷, Andrés Hormaza¹⁸, José Martínez¹⁹, Olga Lidia Vera Lastra²⁰, Hilda Fragoso-Loyo²¹, ⁠Yaneli Juárez-Vicuña²², Diana Fernandez²³, Patricia Langjarth²⁴, Maria Teresa Martinez de Filartiga²⁵, Manuel Ugarte-Gil²⁶, Carlos Alejandro Loayza Flores²⁷, Teresandris Polanco²⁸, Maria Belen Lecumberri²⁹, Álvaro Danza³⁰, Carlos Enrique Toro-Gutierrez³¹, Urbano Sbarigia³², Ashley Orillion³³, Federico Zazzetti³⁴, Graciela Alarcon³⁵, Bernardo Pons-Estel² and Guillermo Pons-Estel³⁶, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ³Hospital Italiano de Córdoba, Cordoba, Argentina, ⁴Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁵Hospital Córdoba, Cordoba, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Plata, Argentina, ⁷Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁸Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ⁹CEMIC Centro de Educación Médica e Investigaciones Clínicas ''Norberto Quirno'' CABA, CABA, Argentina, ¹⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ¹¹Rheumatology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ¹³Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Hospital del Salvador, Santiago, Chile, ¹⁶Centro de Biología Celular y Biomedicina CEBICEM, Facultad de Medicina y Ciencias Universidad San Sebastián, Santiago, Chile, ¹⁷Universidad Simon Bolivar, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²²Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, ²³Member of GLADEL, Rosario, Argentina, ²⁴Hospital de Clínicas I, Asunción, Paraguay, ²⁵Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, ²⁶Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ²⁷Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁸Hospital Docente Padre Billini, Santo Domingo, Dominica, ²⁹Hospital Señor del Milagro, Salta, Argentina, ³⁰Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁵The University of Alabama at Birmingham, Oakland, CA, ³⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…
Abstract Number: 0100 • ACR Convergence 2024
Association Between the Active Form of Plasminogen Activator Inhibitor 1 (PAI-1) and Endothelial Cell Activation in Antiphospholipid Syndrome
Yuzhou Gan¹, Wenying Liang², Mark Warnock³, Srilakshmi Yalavarthi², Cyrus Sarosh⁴, Ajay Tambralli², Jacqueline Madison², Yu Zuo², Daniel Lawrence³ and Jason Knight², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Plasminogen activator inhibitor 1 (PAI-1), a SERPIN-type inhibitor, is best known for regulating fibrinolysis, where it inhibits the activity of tissue and urokinase plasminogen…
Abstract Number: 0116 • ACR Convergence 2024
Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
Reyhan Kose Cobanoglu¹, Joann Vega², Crystal Burgos³ and Doruk Erkan⁴, ¹Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Triple aPL-positive (lupus anticoagulant test [LA], anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody [aβ2GPI]) patients are at higher risk to develop a severe clinical…
Abstract Number: 0837 • ACR Convergence 2024
Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
Yuanxuan Xia¹, Jin Liu¹, Alexander Pearlman¹, Brian Mog¹, Elana Shaw¹, Kyle J. Kaeo¹, Colin Gliech¹, Brock Moritz¹, Tolulope Awosika¹, Sarah DiNapoli¹, Stephanie Glavaris¹, Jiaxin Ge¹, Tushar Nichakawade¹, Nikita Marcou¹, Suman Paul¹, Drew Pardoll¹, Chetan Bettegowda¹, Daniel Goldman², Michelle Petri², Antony Rosen¹, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Available drugs to treat autoimmune diseases are indiscriminate, suppressing self-reactive and protective immune responses alike. This lack of therapeutic precision results in infection and…
Abstract Number: 0101 • ACR Convergence 2024
Metabolomic Profiling Reveals a Role for Citric Acid Cycle Dysfunction in Antiphospholipid Syndrome Neutrophils
Ajay Tambralli¹, Megan Radyk¹, Kaitlyn Sabb¹, Li Zhang¹, Harrison Wong¹, Emily Becker¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Cyrus Sarosh², Jacqueline Madison¹, Yu Zuo¹, Jason Knight¹ and Costas Lyssiotis¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: As early effectors of the immune response, neutrophils must access energy rapidly. Neutrophils rely on glycolysis for antimicrobial functions such as phagocytosis and reactive…
Abstract Number: 0117 • ACR Convergence 2024
Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Daniel Bar¹, Stanley Niznik², Shiri Spielman³, Rotem Semo-Oz⁴, Assaf Barg³, Sarina Levy-Mendelovich³, Gili Kenet², Nancy Agmon- Levin² and Irit Tirosh⁵, ¹Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, HaMerkaz, Israel, ²Sheba Medical Center, Tel Aviv, Israel, ³Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Tel Aviv, Israel, ⁴Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, Israel, ⁵Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Savyon, Israel
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, obstetric morbidity and/or non-thrombotic manifestations. The 2023 ACR/EULAR APS…
Abstract Number: 0838 • ACR Convergence 2024
The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Kavya Sugur¹, Emily Chong¹, Srilakshmi Yalavarthi², Katarina Kmetova³, Lyndsay Kluge¹, Wenying Liang², Cyrus Sarosh⁴, NaveenKumar Somanathapura K², Jacqueline Madison², Ajay Tambralli², Jason Knight² and Yu Zuo², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
Abstract Number: 0102 • ACR Convergence 2024
Single-cell Profiling of Dermal Endothelial Cells Identifies Unique Molecular Pathways Associated with Small-Vessel Events and Nephropathy in Antiphospholipid Syndrome
Wenying Liang¹, Qinmengge Li¹, Jacqueline Madison¹, Rachael Wasikowski², Srilakshmi Yalavarthi¹, Cyrus Sarosh³, Yu Zuo¹, Pei-Suen Tsou¹, Lam Tsoi¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan, Dept. of Dermatology, Ann Arbor, MI, ³University of Michigan, Temperance, MI
Background/Purpose: Beyond thrombotic events, antiphospholipid syndrome (APS) is also associated with an organ-threatening small-vessel vasculopathy that lacks specific treatments. A soon-to-be-published skin biopsy study focusing…
Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Erik Cimé-Aké¹, Gabriela Hernández-Molina², Amaya Llorente-Chávez³ and Eduardo Martin Nares², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Hematology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].